Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial
Annals of Oncology, mdx716, https://doi.org/10.1093/annonc/mdx716 Published: 02 November 2017
Atezolizumab in Combination with Bevacizumab
Atezolizumab in Combination with Bevacizumab in Untreated mRCC: Updated Analysis of IMmotion150 Study [LBA39] Powles T, et al.
Potential Biomarkers of Immunotherapy in NSCLC
Comprehensive Genomic Profiling (CGP) Uncovered Potential Biomarkers of Immunotherapy in NSCLC – Good Predictive Markers: TMB-H, BRAF and MET; Poor Predictive Marker: STK11 [1138PD]
Primary results of LORELEI
Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal patients with ER+/HER2-negative early breast cancer (EBC)[LBA10_PR]
Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC
Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC: CNS Efficacy Result From The ALEX Study [1298O_PR]